Role of leukotriene receptor antagonist in acute severe attack of bronchial asthma in comparison with conventional therapy

ABSTRACT

This study was designed to determine the role of leukotriene receptor antagonist in acute severe attack of bronchial asthma in comparison with conventional therapy. Asthma is a chronic inflammatory lung disease in both the developed and developing countries. Asthmatic patients are at risk of worsening of disease characterized by an increased breathlessness, cough, chest discomfort and wheezing and decreased in expiratory airflow rate. Leukotrienes are lipid mediators synthesized from arachidonic acid, and element of which are potent chemo attractants. These chemical mediators are involved in the pathogenesis of asthma. Study results reveled the effectiveness of leukotriene receptor antagonist in preventing many types of aggravated asthmatic responses. Oral administration of leukotriene receptor antagonist in acute asthmatic patients improves airway function. Once-daily treatment with 10 mg of montelukast, as compared with conventional therapy, provided significant protection against severe broncho-constriction. Study also shows that there was no worsening of the disease. Parameters strongly confirmed the role of leukotriene receptor antagonist when in addition added with steroid therapy in the treatment of acute asthma, there were a smooth improvement was noticed